[Featured Stock] Mico BioMed Rises on Monkeypox Public Health Emergency Concerns

[Asia Economy Reporter Hyungsoo Park] Mikobiomed is showing strong performance. The news that the World Health Organization (WHO) will convene an emergency meeting on the 23rd to consider declaring monkeypox as a Public Health Emergency of International Concern (PHEIC) appears to have influenced the stock price.

As of 9:24 AM on the 15th, Mikobiomed is trading at 11,700 KRW, up 20.12% from the previous day.

According to major foreign media, WHO Director-General Tedros Adhanom Ghebreyesus stated at a press briefing that "the outbreak of monkeypox is unusual and concerning," and "an emergency meeting will be convened to assess whether it constitutes a public health emergency under the International Health Regulations."

The emergency committee meeting, composed of infectious disease experts, is scheduled for the 23rd. PHEIC is the highest level of alert issued by WHO for diseases spreading globally. It is currently applied to COVID-19 and poliomyelitis.

Mikobiomed is expected to promote the export of monkeypox diagnostic devices. Kim Sung-woo, CEO of Mikobiomed, said in a phone interview with the media on the 30th of last month, "We have received inquiries about diagnostic technology from several countries including Europe," and "clinical trials are underway."

Mikobiomed has developed a technology based on the monkeypox virus diagnostic technology developed by the Korea Disease Control and Prevention Agency, enabling rapid real-time diagnosis on-site without special equipment.

This content was produced with the assistance of AI translation services.